​

Vera Therapeutics (VERA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

VERA Stock Forecast

Vera Therapeutics (VERA) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $86.75, with a high of $125.00 and a low of $43.00. This represents a 156.81% increase from the last price of $33.78.

- $30 $60 $90 $120 $150 High: $125 Avg: $86.75 Low: $43 Last Closed Price: $33.78

VERA Stock Rating

Vera Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 1 Strong Buy (7.14%), 12 Buy (85.71%), 1 Hold (7.14%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 1 12 1 Strong Sell Sell Hold Buy Strong Buy

VERA Price Target Upside V Benchmarks

TypeNameUpside
StockVera Therapeutics156.81%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1513
Avg Price Target$84.00$90.60$83.23
Last Closing Price$33.78$33.78$33.78
Upside/Downside148.67%168.21%146.39%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 261121--14
Aug, 261121--14
Jul, 261121--14
Jun, 261121--14
May, 261121--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 11, 2026Ryan DeschnerRaymond James$84.00$30.84172.37%148.67%
Jul 08, 2026Wedbush$43.00$42.960.09%27.29%
Jul 08, 2026Vamil DivanGuggenheim$76.00$42.9676.91%124.99%
Jul 08, 2026Needham$125.00$42.96190.97%270.04%
Jul 08, 2026H.C. Wainwright$125.00$42.96190.97%270.04%
Jun 02, 2026Farzin HaqueJefferies$60.00$31.2691.94%77.62%
Jun 02, 2026Paul ChoiGoldman Sachs$90.00$32.14180.02%166.43%
May 15, 2026Evercore ISI$91.00$38.54136.12%169.39%
Dec 19, 2025Goldman Sachs$95.00$47.6999.20%181.23%
Dec 11, 2025Laura ChicoWedbush$33.00$45.42-27.34%-2.31%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 12, 2026H.C. WainwrightBuyBuyhold
Aug 11, 2026Raymond JamesStrong BuyStrong Buyhold
Jul 08, 2026Cowen & Co.BuyBuyhold
Jul 08, 2026WedbushNeutralNeutralhold
Jul 08, 2026GuggenheimBuyBuyhold
Jul 08, 2026H.C. WainwrightBuyBuyhold
Jun 02, 2026JefferiesBuyBuyhold
Jun 02, 2026William BlairOutperformOutperformhold
Jun 02, 2026Wolfe ResearchOutperformOutperformhold
Jun 02, 2026Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.25$-2.75$-4.66---
Avg Forecast$-2.18$-2.83$-3.15$-3.04$-2.07$0.86
High Forecast$-2.11$-2.65$-2.23$-2.06$-0.09$0.86
Low Forecast$-2.26$-2.99$-4.73$-4.16$-3.80$0.86
Surprise %3.21%-2.83%47.94%---

Revenue Forecast

$0 $110M $220M $330M $440M $550M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast$1.86M$1.86M$1.86M$42.58M$210.59M$516.01M
High Forecast$1.86M$1.86M$1.86M$42.58M$210.59M$516.01M
Low Forecast$1.86M$1.86M$1.86M$42.58M$210.59M$516.01M
Surprise %------

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-95.99M$-152.15M$-299.62M---
Avg Forecast$-95.99M$-120.50M$-148.70M$-133.00M$-154.25M$36.57M
High Forecast$-90.22M$-113.19M$-95.27M$-88.17M$-4.04M$36.57M
Low Forecast$-96.57M$-127.81M$-202.13M$-177.82M$-162.30M$36.57M
Surprise %-26.26%101.48%---

VERA Forecast FAQ

Is Vera Therapeutics stock a buy?

Vera Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 12 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Vera Therapeutics is a favorable investment for most analysts.

What is Vera Therapeutics's price target?

Vera Therapeutics's price target, set by 14 Wall Street analysts, averages $86.75 over the next 12 months. The price target range spans from $43 at the low end to $125 at the high end, suggesting a potential 156.81% change from the previous closing price of $33.78.

How does Vera Therapeutics stock forecast compare to its benchmarks?

Vera Therapeutics's stock forecast shows a 156.81% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Vera Therapeutics over the past three months?

  • September 2026: 7.14% Strong Buy, 85.71% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 7.14% Strong Buy, 85.71% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 7.14% Strong Buy, 85.71% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.

What is Vera Therapeutics’s EPS forecast?

Vera Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.04, marking a -34.76% decrease from the reported $-4.66 in 2025. Estimates for the following years are $-2.07 in 2027, and $0.86 in 2028.

What is Vera Therapeutics’s revenue forecast?

Vera Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $42.58M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $210.59M, and $516.01M for 2028.

What is Vera Therapeutics’s net income forecast?

Vera Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-133M, representing a -55.61% decrease from the reported $-300M in 2025. Projections indicate $-154M in 2027, and $36.57M in 2028.